Oxurion NV (BR:OXUR) — Market Cap & Net Worth
Market Cap & Net Worth: Oxurion NV (OXUR)
Oxurion NV (BR:OXUR) has a market capitalization of $311.07K (€266.07K) as of June 16, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #30994 globally and #113 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oxurion NV's stock price €0.00 by its total outstanding shares 88691312 (88.69 Million). Review OXUR total debt and obligations to assess the company's total debt and financial obligations.
Oxurion NV Market Cap History: 2015 to 2026
Oxurion NV's market capitalization history from 2015 to 2026. Data shows change from $3.73 Trillion to $311.07K (-78.30% CAGR).
Index Memberships
Oxurion NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$854.24 Billion | 0.00% | #107 of 108 |
Weight: Oxurion NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oxurion NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oxurion NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8295.16x
Oxurion NV's market cap is 8295.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
209.12x
Oxurion NV's market cap is 209.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.73 Trillion | $11.20 Million | -$37.88 Million | 333347.09x | N/A |
| 2016 | $2.62 Trillion | $7.10 Million | -$60.31 Million | 369130.99x | N/A |
| 2017 | $3.51 Trillion | $5.81 Million | $22.79 Million | 603754.66x | 153932.53x |
| 2018 | $3.75 Trillion | $5.32 Million | -$38.47 Million | 705556.13x | N/A |
| 2019 | $3.06 Trillion | $3.95 Million | -$51.83 Million | 775174.66x | N/A |
| 2020 | $2.65 Trillion | $2.08 Million | -$28.01 Million | 1274911.36x | N/A |
| 2021 | $1.88 Trillion | $1.13 Million | -$29.16 Million | 1669326.83x | N/A |
| 2022 | $19.70 Billion | $595.00K | -$31.68 Million | 33110.92x | N/A |
| 2023 | $933.21 Million | $263.00K | -$18.97 Million | 3548.31x | N/A |
| 2024 | $24.89 Million | $3.00K | $119.00K | 8295.16x | 209.12x |
Competitor Companies of OXUR by Market Capitalization
Companies near Oxurion NV in the global market cap rankings as of June 16, 2026.
Key companies related to Oxurion NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Oxurion NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Oxurion NV's market cap moved from $3.73 Trillion to $ 311.07K, with a yearly change of -78.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €311.07K | -58.33% |
| 2025 | €746.56K | -97.00% |
| 2024 | €24.89 Million | -97.33% |
| 2023 | €933.21 Million | -95.26% |
| 2022 | €19.70 Billion | -98.95% |
| 2021 | €1.88 Trillion | -28.92% |
| 2020 | €2.65 Trillion | -13.39% |
| 2019 | €3.06 Trillion | -18.51% |
| 2018 | €3.75 Trillion | +7.01% |
| 2017 | €3.51 Trillion | +33.77% |
| 2016 | €2.62 Trillion | -29.75% |
| 2015 | €3.73 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Oxurion NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $311.07K USD |
| MoneyControl | $311.07K USD |
| MarketWatch | $311.07K USD |
| marketcap.company | $311.07K USD |
| Reuters | $311.07K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more